Elevance Health Inc.
High uncertainty:The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
8.3% vs price
Base Case (Median)
100.0% vs price
Bull Case (75th pct.)
947.2% vs price
◇ = Current price | |Bear |Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $0.00 | -100.0% | High (40%) |
| PE Comparable | $5053.39 | 947.2% | Medium (25%) |
| Growth Trajectory DCF | $5192.55 | 976.0% | Medium (20%) |
| Graham Number | $964.92 | 99.9% | Medium (40%) |
| EV/FCF | $522.56 | 8.3% | Medium (20%) |
Based on 5 out of 8 methods, ANTM appears undervalued at the current price of $482.58. The base case fair value of $964.92 implies 100.0% upside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.